AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs NORTH CHICAGO, Ill. , Sept. 17, 2026 / PRNewswire / -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23 rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results  demonstrated  statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM).  Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings. Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes, reinforcing AbbVie's strategy to advance understanding of disease heterogeneity, mechanisms of resistance and the evolving needs of patients living with multiple myeloma. "Despite meaningful progress in multiple myeloma, the disease remains incurable and patients continue to face challenges related to treatment resistance, disease heterogeneity, tolerability and durable disease control," said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology at AbbVie. "Our presence at IMS reflects the depth and momentum of our multiple myeloma strategy as we advance our scientifically differentiated portfolio, spanning T-cell engagers, targeted therapies and rational combinations designed to address distinct disease mechanisms and evolving patient needs, with the goal of delivering more precise, durable and accessible treatment options." The full list of AbbVie presentations at IMS includes: Note: All presentation times are listed in local Glasgow time. Abstract Title Date/Time Session Abstract Number Real-World (RW) Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in Europe: Results from the HARMONY Big Data Platform   Wednesday, September 23, 2026   12:00–1:00 PM Poster Presentation   PA-386 Etentamig in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B- Cell Maturation Antigen (BCMA)-Targeted Therapy   Thursday, September 24, 2026   12:00–1:00 PM Poster Presentation   PA-181 A Phase 1/2, Open-Label, Platform Study to Evaluate the Safety and Efficacy of Etentamig Monotherapy or Combination Therapy in Patients with Multiple Myeloma   Friday, September 25, 2026   12:00–1:00 PM Poster Presentation   PA-008 Phase 1/2, Open-Label, Platform Study of Surzetoclax with Etentamig in Biomarker- Selected Patients with Relapsed/Refractory Multiple Myeloma (RRMM)   Friday, September 25, 2026   12:00–1:00 PM Poster Presentation PA-346 Real-World (RW) Infection-Related Healthcare Resource Utilization (HCRU) and Costs in Patients (pts) with Multiple Myeloma (MM) Receiving T-cell Redirecting Therapies (TCRTs)   Friday, September 25, 2026   12:00–1:00 PM Poster Presentation   PA-387 CERVINO: Phase (Ph) 3 Results of Etentamig vs Investigator's Choice of Standard Available Therapies (SAT) in Patients (Pts) With Triple- Class Exposed Relapsed or Refractory Multiple Myeloma (RRMM)   Friday, September 25, 2026   3:00–5:00 PM Plenary Session   Hall 5 LBA-01 Etentamig Combined With Pomalidomide Plus Dexamethasone (Pom+Dex) in Relapsed/ Refractory Multiple Myeloma (RRMM) After 1–3 Prior Lines of Therapy: A Phase 1b Dose- Escalation and Safety Expansion Study   Saturday, September 26, 2026   8:30–9:30 AM   Oral Presentation   Abstract Session 9   Hall 5 OA-24 AbbVie Advances ABBV- 2001/ISB 2001: A Unique, Single-Molecule Trispecific T-cell Engager (TCE) Approach Toward Robust Anti-Myeloma Activity with Superior Tumor Cytotoxicity   Saturday, September 26, 2026   9:30–10:20 AM Oral Presentation   Future Targets and New Modalities of Therapy   Hall 5   N/A Surzetoclax: A Potentially Best-in-Class BCL-2 Inhibitor for the Treatment of Multiple Myeloma with t(11;14) Translocation or High BCL-2 Expression   N/A Poster Presentation   PA-468 — Company newsroom — sourced from AbbVie. Matter furnished by the company. Not a Notice Nearby paid placement. This page reprints matter furnished by the company from its official newsroom. Notice Nearby did not write this release. Read the original: https://news.abbvie.com/2026-09-17-AbbVie-to-Present-Phase-3-Etentamig-Results-and-Data-from-Broad-Multiple-Myeloma-Portfolio-at-the-2026-International-Myeloma-Society-IMS-Meeting